Abstract 1303P
Background
To construct a Nomogram model based on clinical variables to predict the overall survival (OS) for NSCLC patients receiving atezolizumab.
Methods
The patients receiving atezolizumab from OAK and POPLAR study were enrolled in our study. Specifically, the 424 patients with NSCLC receiving atezolizumab from OAK study were regarded as the training cohort, and the 144 patients with NSCLC receiving atezolizumab from POPLAR study were regarded as the test cohort. The training cohort was applied to construct the Nomogram model distinguishing the high risk and low risk population based on the clinical variables. The Kaplan-Meier method was used to compare the OS difference between the high risk and low risk population. Importantly, the test cohort was used to validate the OS difference of risk group derived from the Nomogram model.
Results
We successfully constructed a Nomogram model based on different variable score including race, sex, histopathology, ECOG, blSLD and metastasis sites for patients with NSCLC receiving atezolizumab from OAK study. The patients receiving atezolizumab were divided into high riskand low risk group according to the Nomogram model. Importantly, the worse OS was found in high-risk patients compared with the low-risk patients (median survival: 252.3 vs. 556.9 days; P<0.0001). As our expected, the high-risk patients in the test cohort from POPLRA study also showed a worse OS compared with low-risk patients (median survival: 288.8 vs. 529.3 days, P = 0.0003). In addition, all the patients from training and test cohort could be found the OS benefit from atezolizumab compared with docetaxel (all, P<0.05).
Conclusions
The clinical variable based-Nomogram model could predict OS benefit for patients with NSCLC receiving atezolizumab.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
H. Wang.
Funding
This study was supported jointly by Special Funds for Taishan Scholars Project (Grant No. tsqn201812149), Academic promotion program of Shandong First Medical University (2019RC004).
Disclosure
All authors have declared no conflicts of interest.